Validated High Performance Liquid Chromatographic Method for Simultaneous Determination of Rosiglitazone, Cilostazol, and 3,4-Dehydro-cilostazol in Rat Plasma and its Application to Pharmacokinetics

Abstract

A high performance liquid chromatographic (HPLC) method for simultaneous determination of rosiglitazone, CAS 122320-73-4, RSG), cilostazol (CAS 73963-72-1, CLZ) and its active metabolite 3, 4-dehydro-cilostazol (DCLZ), using pioglitazone (PIO) as internal standard (IS), in rat plasma is described. The plasma was extracted with methyl t-butyl ether, the dry extract was reconstituted in mobile phase and the aliquot was injected. The eluent drugs were detected by UV at dual wavelength of 226 nm (RSG and DCLZ) and 257nm (CLZ). The mobile phase consisting of acetonitrile:potassium di-hydrogen phosphate buffer (35:65 v/v) was used at the flow rate of 1.2 ml/min on a reverse phase C₁₈ column. The absolute recovery was above 90 % of all analytes over the concentration range of 25-2500 ng/ml for RSG and CLZ and 20-2000 ng/ml for DCLZ. The relative standard deviation (RSD) of the inter-day and intra-day precision ranged from 2.8 to 8.4 % and 0.9 to 5.9 %, respectively. The method is simple, rapid, accurate and sensitive and was applied to pharmacokinetic studies.

Key words

Antidiabetics - CAS 73963-72-1 - CAS 122320-73-4 - Cilostazol, determination in rat plasma, HPLC-UV, pharmacokinetics - 3, 4-Dehydro-cilostazol, determination in rat plasma, HPLC-UV, pharmacokinetics - Drug-drug interactions - Rosiglitazone, determination in rat plasma, HPLC-UV, pharmacokinetics

• Literature

• 1 Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004; 26: 177-190
• 2 Miller JL. Rosiglitazone approved for treatment of type 2 diabetes. Am J Health Syst Pharm. 1999; 56: 1292-1294
• 3 Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000; 28: 772-780
• 4 Chapman TM, and Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003; 3: 117-138
• 5 Schror K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002; 4 (Suppl 2) S14-19
• 6 Abbas R, Chow CP, Browder NJ, Thacker D, Bramer SL, Fu CJ et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol. 2000; 19: 178-184
• 7 Akiyama H, Kudo S, and Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittel-Forschung (Drug Research). 1985; 35: 1133-1140
• 8 Bramer SL, Tata PN, Vengurlekar SS, and Brisson JH. Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS. J Pharm Biomed Anal. 2001; 26: 637-650
• 9 Akiyama H, Kudo S, Odomi M, and Shimizu T. High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma. J Chromatogr. 1985; 338: 456-459
• 10 Fu CJ, Tata PN, Okada K, Akiyama H, and Bramer SL. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999; 728: 251-262
• 11 Tata PN, Fu CH, and Bramer SL. Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography. J Pharm Biomed Anal. 2001; 24: 381-389
• 12 Tata PN, Fu CH, Browder NJ, Chow PC, and Bramer SL. The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography. J Pharm Biomed Anal. 1998; 18: 441-451
• 13 Hruska MW, and Frye RF. Simplified method for determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 803: 317-320
• 14 Kim KA, and Park JY. Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. Biomed Chromatogr. 2004; 18: 613-615
• 15 Mamidi RN, Benjamin B, Ramesh M, and Srinivas NR. Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomed Chromatogr. 2003; 17: 417-420
• 16 Mamidi RN, Chaluvadi MR, Benjamin B, Ramesh M, Katneni K, Babu AP et al. HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study. Arzneimittel-Forschung (Drug Research). 2002; 52: 560-564
• 17 Kolte BL, Raut BB, Deo AA, Bagool MA, and Shinde DB. Liquid chromatographic method for the determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 788: 37-44
• 18 Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde D. Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography. J Chromatogr Sci. 2004; 42: 70-73
• 19 Lin ZJ, Desai-Krieger D and Shum L. Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 801: 265-272